Following the second committee meeting on 13 April 2023 for rimegepant for treating or preventing migraine [ID1539], this topic has been split into its 2 indications.
Rimegepant for treating acute migraine will retain ID1539. Rimegepant for preventing episodic migraine will use ID6275.